ArQule Company Profile (NASDAQ:ARQL)

About ArQule (NASDAQ:ARQL)

ArQule, Inc. is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug candidates, all of which are in targeted patient populations. The Company's lead product candidate is tivantinib (ARQ 197), an orally administered, small molecule inhibitor of the c-Met receptor tyrosine kinase (MET) and its biological pathway. The Company's product candidates include ARQ 092, designed to inhibit the AKT serine/threonine kinase; ARQ 087, a multi-kinase inhibitor designed to inhibit the fibroblast growth factor receptor (FGFR) family, and ARQ 761, a Beta lapachone analog being evaluated in investigator-sponsored testing as a promoter of NQO1-mediated programmed cancer cell necrosis.

Industry, Sector and Symbol:

Sector: Medical
Industry: Biotechnology & Medical Research
Sub-Industry: Biotechnology
Symbol: NASDAQ:ARQL
CUSIP: 04269E10
Web: www.arqule.com

Capitalization:

Market Cap: $81.85 million
Outstanding Shares: 71,171,000

Average Prices:

50 Day Moving Avg: $1.09
200 Day Moving Avg: $1.13
52 Week Range: $0.92 - $1.82

P/E:

Trailing P/E Ratio: N/A
Foreward P/E Ratio: -2.80
P/E Growth: -0.53

Sales & Book Value:

Annual Revenue: $2.41 million
Price / Sales: 33.08
Book Value: $0.14 per share
Price / Book: 8.00

Profitability:

EBIDTA: ($26,760,000.00)
Net Margins: -482.44%
Return on Equity: -135.68%
Return on Assets: -77.68%

Debt:

Debt-to-Equity Ratio: 1.43%
Current Ratio: 4.33%
Quick Ratio: 4.33%

Misc:

Average Volume: 127,527 shs.
Beta: 1.51
Short Ratio: 10.48

Frequently Asked Questions for ArQule (NASDAQ:ARQL)

What is ArQule's stock symbol?

ArQule trades on the NASDAQ under the ticker symbol "ARQL."

How were ArQule's earnings last quarter?

ArQule, Inc. (NASDAQ:ARQL) issued its quarterly earnings data on Friday, August, 4th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.11) by $0.01. ArQule had a negative return on equity of 135.68% and a negative net margin of 482.44%. During the same period last year, the business posted ($0.07) earnings per share. View ArQule's Earnings History.

When will ArQule make its next earnings announcement?

ArQule is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for ArQule.

Who are some of ArQule's key competitors?

Some companies that are related to ArQule include Asterias Biotherapeutics (AST), Asterias Biotherapeutics (AST), Genocea Biosciences (GNCA), Pluristem Therapeutics (PSTI), GTx (GTXI), Regulus Therapeutics (RGLS), CTI BioPharma Corp. (CTIC), Silence Therapeutics plc (SLN), Novelion Therapeutics (NVLN), Oramed Pharmaceuticals (ORMP), Matinas BioPharma Holdings (MTNB), BioLineRx (BLRX), CASI Pharmaceuticals (CASI), Palatin Technologies (PTN), aTyr Pharma (LIFE), Tissue Regenix Group PLC (TRX), Eiger BioPharmaceuticals (EIGR) and Zynerba Pharmaceuticals (ZYNE).

Who are ArQule's key executives?

ArQule's management team includes the folowing people:

Patrick J. Zenner, Independent Chairman of the Board
Peter S. Lawrence, President, Chief Operating Officer
Paolo Pucci, Chief Executive Officer, Director
Robert J. Weiskopf, Chief Financial Officer, Treasurer
Brian Schwartz M.D., Chief Medical Officer
Timothy C. Barabe, Independent Director
Susan L. Kelley M.D., Independent Director
Ronald M. Lindsay Ph.D., Independent Director
Michael D. Loberg Ph.D., Independent Director
William G. Messenger D. Min., Independent Director

Who owns ArQule stock?

ArQule's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include First Eagle Investment Management LLC (16.65%), Vanguard Group Inc. (3.63%), NEA Management Company LLC (3.54%), DAFNA Capital Management LLC (1.10%), California Public Employees Retirement System (0.32%) and Northern Trust Corp (0.22%). Company insiders that own ArQule stock include Michael D Loberg, Paolo Pucci and Patrick J Zenner. View Institutional Ownership Trends for ArQule.

Who sold ArQule stock? Who is selling ArQule stock?

ArQule's stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc. and DAFNA Capital Management LLC. View Insider Buying and Selling for ArQule.

Who bought ArQule stock? Who is buying ArQule stock?

ArQule's stock was bought by a variety of institutional investors in the last quarter, including First Eagle Investment Management LLC and Northern Trust Corp. Company insiders that have bought ArQule stock in the last two years include Michael D Loberg, Paolo Pucci and Patrick J Zenner. View Insider Buying and Selling for ArQule.

How do I buy ArQule stock?

Shares of ArQule can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ArQule's stock price today?

One share of ArQule stock can currently be purchased for approximately $1.12.

MarketBeat Community Rating for ArQule (NASDAQ ARQL)

Community Ranking:		2.4 out of 5 ( )
Outperform Votes:		88 (Vote Outperform)
Underperform Votes:		99 (Vote Underperform)
Total Votes:		187

MarketBeat's community ratings are surveys of what our community members think about ArQule and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Consensus Ratings for ArQule (NASDAQ:ARQL) (How are Consensus Ratings Calculated?)

Ratings Breakdown:	No ratings tracked in the last 12 months.
Consensus Rating:	N/A (Score: NaN)
Consensus Price Target:	N/A

Analysts' Ratings History for ArQule (NASDAQ:ARQL)

Show:

Date	Firm	Action	Rating	Price Target	Impact on Share Price	Details
3/1/2016	Leerink Swann	Lower Price Target	Market Perform	$3.00 -> $2.50	N/A
12/27/2015	Royal Bank Of Canada	Upgrade	Buy		N/A

(Data available from 9/22/2015 forward)

Earnings History for ArQule (NASDAQ:ARQL)

Earnings by Quarter for ArQule (NASDAQ:ARQL)

Earnings History by Quarter for ArQule (NASDAQ ARQL)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
11/6/2017		($0.11)					N/A
8/4/2017	Q2 2017	($0.11)	($0.10)			View	N/A
5/3/2017	Q1 2017	($0.11)	($0.11)			View	Listen
3/7/2017	Q4 2016	($0.10)	($0.10)	$1.20 million	$1.19 million	View	Listen
11/7/2016	Q316	($0.09)	($0.08)	$1.10 million	$1.22 million	View	Listen
8/3/2016	Q216	($0.08)	($0.07)	$1.13 million	$1.07 million	View	N/A
5/4/2016	Q116	($0.07)	($0.08)	$1.63 million	$1.28 million	View	N/A
2/29/2016	Q415	($0.06)	($0.05)	$2.40 million	$2.80 million	View	Listen
11/4/2015	Q315	($0.08)	($0.04)	$2.60 million	$2.65 million	View	N/A
8/5/2015	Q215	($0.08)	($0.06)	$2.50 million	$3.04 million	View	N/A
5/6/2015	Q115	($0.08)	($0.07)	$1.98 million	$2.79 million	View	N/A
3/4/2015	Q414	($0.13)	($0.06)	$1.90 million	$3.02 million	View	N/A
11/10/2014	Q314	($0.13)	($0.10)	$2.20 million	$2.66 million	View	N/A
8/5/2014	Q214	($0.13)	($0.10)	$2.43 million	$2.90 million	View	N/A
5/7/2014	Q114	($0.11)	($0.11)	$2.29 million	$2.67 million	View	N/A
3/5/2014	Q413	($0.13)	($0.10)	$2.27 million	$2.28 million	View	N/A
10/31/2013	Q313	($0.13)	($0.10)	$2.77 million	$3.50 million	View	N/A
7/30/2013	Q2 2013	($0.12)	($0.11)	$3.84 million	$4.44 million	View	N/A
5/8/2013	Q1 2013	($0.11)	($0.09)	$3.78 million	$5.66 million	View	N/A
3/14/2013	Q4 2012	($0.13)	($0.09)	$5.17 million	$5.14 million	View	N/A
11/1/2012		($0.07)	($0.01)			View	N/A
8/2/2012		($0.07)	($0.01)			View	N/A
5/3/2012		($0.07)	($0.08)			View	N/A
3/1/2012		($0.09)	$0.07			View	N/A
11/10/2011		($0.23)	($0.04)			View	N/A
8/4/2011		($0.19)	($0.20)			View	N/A
5/5/2011		($0.08)	($0.03)			View	N/A
3/1/2011		($0.15)	($0.13)			View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for ArQule (NASDAQ:ARQL)

2017 EPS Consensus Estimate: ($0.45)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2017	1	($0.10)	($0.10)	($0.10)
Q2 2017	1	($0.11)	($0.11)	($0.11)
Q3 2017	1	($0.12)	($0.12)	($0.12)
Q4 2017	1	($0.12)	($0.12)	($0.12)

(Data provided by Zacks Investment Research)

Dividend History for ArQule (NASDAQ:ARQL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading and Institutional Ownership History for ArQule (NASDAQ:ARQL)

Insider Ownership Percentage: 9.00%
Institutional Ownership Percentage: 60.95%

Institutional Ownership by Quarter for ArQule (NASDAQ:ARQL)

Insider Trades by Quarter for ArQule (NASDAQ:ARQL)

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
9/7/2017	Paolo Pucci	CEO	Buy	1,101	$1.15	$1,266.15
9/6/2017	Paolo Pucci	CEO	Buy	16,397	$1.15	$18,856.55
9/5/2017	Paolo Pucci	CEO	Buy	19,156	$1.14	$21,837.84
8/29/2017	Paolo Pucci	CEO	Buy	300	$1.05	$315.00
8/28/2017	Paolo Pucci	CEO	Buy	2,970	$1.05	$3,118.50
8/25/2017	Paolo Pucci	Insider	Buy	9,492	$1.05	$9,966.60
12/17/2015	Michael D Loberg	Director	Buy	3,719	$2.16	$8,033.04
12/16/2015	Michael D Loberg	Director	Buy	1,231	$2.14	$2,634.34
12/15/2015	Paolo Pucci	CEO	Buy	1,283	$2.16	$2,771.28
12/11/2015	Paolo Pucci	CEO	Buy	1,108	$2.10	$2,326.80
12/11/2015	Patrick J Zenner	Director	Buy	2,300	$2.15	$4,945.00
12/10/2015	Paolo Pucci	CEO	Buy	7,609	$2.10	$15,978.90
3/11/2015	Patrick J Zenner	Director	Buy	10,625	$2.32	$24,650.00
11/20/2014	Paolo Pucci	CEO	Buy	5,000	$1.26	$6,300.00
11/14/2014	Patrick J Zenner	Director	Buy	20,830	$1.20	$24,996.00
11/13/2014	Susan L Kelley	Director	Buy	50,000	$1.20	$60,000.00
9/4/2014	Paolo Pucci	CEO	Buy	5,000	$1.31	$6,550.00
5/23/2014	Paolo Pucci	CEO	Buy	5,000	$1.40	$7,000.00
5/20/2014	Paolo Pucci	CEO	Buy	5,000	$1.42	$7,100.00
3/17/2014	Patrick Zenner	Director	Buy	4,715	$2.12	$9,995.80
3/13/2014	Paolo Pucci	CEO	Buy	10,000	$2.10	$21,000.00

(Data available from 1/1/2013 forward)

Headline Trends for ArQule (NASDAQ:ARQL) Latest Headlines for ArQule (NASDAQ:ARQL)

Source:

Date	Headline
	ArQule to Present at the Cantor Fitzgerald Global Healthcare Conference on September 26, 2017 finance.yahoo.com - September 19 at 4:03 PM
	ArQule, Inc. (ARQL) Expected to Announce Earnings of -$0.12 Per Share www.americanbankingnews.com - September 18 at 4:28 PM
	ArQule, Inc. (ARQL) Upgraded by Zacks Investment Research to Buy www.americanbankingnews.com - September 15 at 4:22 PM
	ArQule, Inc. (ARQL) Downgraded by Zacks Investment Research to Hold www.americanbankingnews.com - September 14 at 4:50 PM
	ArQule, Inc. (ARQL) Rating Increased to Buy at Zacks Investment Research www.americanbankingnews.com - September 8 at 5:02 PM
	Insider Buying: ArQule, Inc. (ARQL) CEO Acquires 16,397 Shares of Stock www.americanbankingnews.com - September 7 at 1:46 PM
	Zacks Investment Research Lowers ArQule, Inc. (ARQL) to Hold www.americanbankingnews.com - September 6 at 8:28 PM
	ArQule, Inc. (ARQL) CEO Paolo Pucci Acquires 19,156 Shares www.americanbankingnews.com - September 6 at 1:38 PM
	ValuEngine Downgrades ArQule, Inc. (ARQL) to Strong Sell www.americanbankingnews.com - September 3 at 10:10 PM
	ArQule, Inc. (ARQL) Lifted to "Buy" at Zacks Investment Research www.americanbankingnews.com - August 23 at 4:46 PM
	ArQule, Inc. (ARQL) Rating Lowered to Hold at Zacks Investment Research www.americanbankingnews.com - August 18 at 6:58 PM
	ArQule, Inc. (NASDAQ:ARQL) to Post FY2017 Earnings of ($0.44) Per Share, Leerink Swann Forecasts www.americanbankingnews.com - August 10 at 1:50 PM
	Edited Transcript of ARQL earnings conference call or presentation 4-Aug-17 1:00pm GMT finance.yahoo.com - August 4 at 9:46 PM
	ArQule's (ARQL) CEO Paolo Pucci on Q2 2017 Results - Earnings Call Transcript seekingalpha.com - August 4 at 4:23 PM
	ArQule Reports Second Quarter 2017 Financial Results finance.yahoo.com - August 4 at 4:23 PM
	ArQule reports 2Q loss finance.yahoo.com - August 4 at 4:23 PM
	ArQule, Inc. (ARQL) Announces Earnings Results, Beats Estimates By $0.01 EPS www.americanbankingnews.com - August 4 at 3:33 PM
	ArQule, Inc. (ARQL) Expected to Announce Earnings of -$0.11 Per Share www.americanbankingnews.com - July 25 at 12:25 PM
	ArQule, Inc. (NASDAQ:ARQL) Set to Announce Earnings on Tuesday www.americanbankingnews.com - July 25 at 7:10 AM
	ArQule To Report Second Quarter 2017 Financial Results On August 4, 2017 finance.yahoo.com - July 21 at 5:28 PM
	ArQule: First Patient Dosed In ARQ 531 Phase 1 Trial For B-cell Malignancies www.rttnews.com - July 12 at 1:40 AM
	ArQule Announces First Patient Dosed in Phase 1 Trial of BTK Inhibitor, ARQ 531, for B-cell Malignancies finance.yahoo.com - July 11 at 3:38 PM
	SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating ArQule, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors finance.yahoo.com - June 26 at 4:08 PM
	ArQule (ARQL) Presents Preclinical Data for BTK Inhibitor, ARQ 531, at EHA www.streetinsider.com - June 24 at 8:48 PM
	ArQule Presents Preclinical Data for BTK Inhibitor, ARQ 531, at the 22nd Annual Congress of the European Hematology Association (EHA) finance.yahoo.com - June 23 at 4:15 PM
	ArQule Announces First Patient Dosed in Company Sponsored Phase 1/2 Trial of AKT Inhibitor, ARQ 092, for Rare Overgrowth Diseases finance.yahoo.com - June 7 at 3:50 PM
	Analysts Expect ArQule, Inc. (ARQL) to Announce -$0.11 EPS www.americanbankingnews.com - June 5 at 7:37 AM
	ArQule Presents Phase 1/2 Clinical Data with ARQ 087 in Intrahepatic Cholangiocarcinoma at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting finance.yahoo.com - June 3 at 3:40 PM
	ArQule Presents Phase 1/2 Clinical Data with ARQ 087 in Intrahepatic Cholangiocarcinoma at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting finance.yahoo.com - June 3 at 3:40 PM
	ArQule Stock Up 28% on Lab Data for B-Cell Lymphoma Drug www.baystreet.ca - May 19 at 9:27 AM
	ArQule to Present Preclinical Data for BTK Inhibitor, ARQ 531, at the 22nd Annual Congress of the European Hematology Association (EHA) finance.yahoo.com - May 18 at 12:06 PM
	ArQule to Present Clinical Data at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting finance.yahoo.com - May 17 at 8:40 PM
	ArQule, Inc. (ARQL) Short Interest Update www.americanbankingnews.com - May 15 at 8:48 AM
	-$0.11 EPS Expected for ArQule, Inc. (ARQL) This Quarter www.americanbankingnews.com - May 9 at 6:16 PM
	Leerink Swann Brokers Cut Earnings Estimates for ArQule, Inc. (ARQL) www.americanbankingnews.com - May 8 at 8:26 AM
	ArQule, Inc. (ARQL) Downgraded to "Sell" at Zacks Investment Research www.americanbankingnews.com - May 4 at 7:06 PM
	Edited Transcript of ARQL earnings conference call or presentation 3-May-17 1:00pm GMT finance.yahoo.com - May 4 at 1:47 AM
	ArQule, Inc. (ARQL) Issues Earnings Results, Meets Expectations www.americanbankingnews.com - May 3 at 12:33 PM
	Arqule Reports First Quarter 2017 Financial Results finance.yahoo.com - May 3 at 9:55 AM
	ArQule reports 1Q loss finance.yahoo.com - May 3 at 9:55 AM
	Investor Network: ArQule, Inc. to Host Earnings Call finance.yahoo.com - May 3 at 9:55 AM
	ArQule (ARQL) Earns Daily Media Impact Rating of 0.13 www.americanbankingnews.com - May 2 at 8:16 AM
	ArQule, Inc. (ARQL) Scheduled to Post Earnings on Wednesday www.americanbankingnews.com - May 1 at 11:56 AM
	ArQule (ARQL) Receiving Somewhat Favorable News Coverage, Report Shows www.americanbankingnews.com - April 27 at 4:38 PM
	ArQule Announces Issuance of U.S. Patent Covering Composition of Matter of Proprietary Reversible BTK Inhibitor, ARQ 531 finance.yahoo.com - April 26 at 9:10 AM
	ArQule (ARQL) Earning Somewhat Positive Press Coverage, Report Finds www.americanbankingnews.com - April 20 at 2:42 PM
	ArQule To Report First Quarter 2017 Financial Results On May 3, 2017 finance.yahoo.com - April 19 at 9:15 AM
	-$0.10 EPS Expected for ArQule, Inc. (ARQL) This Quarter www.americanbankingnews.com - April 18 at 10:21 PM
	Somewhat Favorable Media Coverage Somewhat Likely to Impact ArQule (ARQL) Stock Price www.americanbankingnews.com - April 17 at 12:07 PM
	Somewhat Critical Press Coverage Somewhat Likely to Effect ArQule (ARQL) Share Price www.americanbankingnews.com - April 14 at 7:58 AM